Apyx Medical (Apyx Medical) LT-Debt-to-Total-Asset : 0.54 (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Apyx Medical's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.54.

Apyx Medical's long-term debt to total assets ratio increased from Mar. 2023 (0.01) to Mar. 2024 (0.54). It may suggest that Apyx Medical is progressively becoming more dependent on debt to grow their business.

Apyx Medical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Apyx Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical LT-Debt-to-Total-Asset Chart

Apyx Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.48

Apyx Medical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.08	0.24	0.48	0.54

Apyx Medical LT-Debt-to-Total-Asset Calculation

Apyx Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	38.134	/	79.24
	=	0.48

Apyx Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	38.249	/	70.711
	=	0.54

Apyx Medical (NAS:APYX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Apyx Medical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Apyx Medical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Apyx Medical (Apyx Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BOV:Germany

Address

5115 Ulmerton Road, Clearwater, FL, USA, 33760

Website

https://apyxmedical.com

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Executives

Todd Hornsby	officer: Executive Vice President	14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine	director	75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb	officer: Chief Financial Officer	5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal	director	5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty	director	1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman	director	5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres	director	86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers	officer: Chief Financial Officer	4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron	director, officer: President
Robert Gershon	director, officer: Chief Executive Officer	5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii	officer: Chief CommercializationOfficer	23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson	director	C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz	officer: Vice President of Operations